

STUDIES ON THE MODE OF ACTION OF CALCIFEROL. X.
24-NOR-25-HYDROXYVITAMIN D₃, AN ANALOG OF 25-HYDROXYVITAMIN D₃
HAVING "ANTI-VITAMIN" ACTIVITY

R. Lorne Johnson*, William H. Okamura⁺ and Anthony W. Norman*

Departments of Biochemistry* and Chemistry⁺
University of California
Riverside, California 92502

Received September 22, 1975

Summary

24-Nor-25-hydroxyvitamin D₃, an analog of 25-hydroxyvitamin D₃, has been chemically synthesized in six steps. This steroid was tested in chicks, *in vivo*, for its ability to generate the classic vitamin D mediated responses of stimulation of intestinal calcium transport and bone calcium mobilization. Although the 24-nor-25-OH-vitamin D₃ itself exhibited no biological activity in these assays, the analog was found to inhibit the normal responses produced by a physiological dose of vitamin D₃. These results suggest that 24-nor-25-OH-vitamin D₃ may satisfy certain requirements expected of a calciferol "anti-vitamin."

It is well established that the biologically significant form of vitamin D₃ is 1 α ,25-dihydroxyvitamin D₃¹ (1, 2). This form of the vitamin is made by successive obligatory hydroxylations of vitamin D; first by the liver at the C-25 position to give 25-hydroxyvitamin D₃ (3) and second by the kidney at the C-1 α position (4, 5). (See Figure 1)

It is apparent that in the complex metabolic pathway or endocrine system required to produce 1 α ,25-(OH)₂-D₃, that there are many sites of steroid-protein(enzymes, carrier proteins and ultimately receptor) interaction.

In our continuing efforts to elucidate the minimal and optimal structural features of the vitamin D molecule required for biological activity, we have initiated a program of synthesis of a series of side chain analogs of 25-OH-D₃ in which the 8 carbon side chain of vitamin D₃ is extended by one carbon or shortened by 1,2,3 or 5 carbons, but always with retention of the tertiary

¹Abbreviations employed are: 25-hydroxyvitamin D₃ [25-OH-D₃]; 1 α ,25-dihydroxyvitamin D₃ [1 α ,25-(OH)₂-D₃]; 24-nor-25-hydroxyvitamin D₃ [24-nor-25-OH-D₃]; 24,25-dihydroxyvitamin D₃ [24,25-(OH)₂-D₃].




Figure 1. Vitamin D and related compounds. For vitamin D₃, 1, (when R₁ = R₂ = H); 25-OH-D₃, 2, (when R₁ = OH, R₂ = H); 1α,25-(OH)₂-D₃, 3 (when R₁ = R₂ = OH); For 4 steroid shown is 24-nor-25-OH-D₃.

hydroxyl group (6). In this communication we wish to report the improved chemical synthesis and previously unrecognized biological properties of the analog 24-nor-25-OH-D₃ in which the side chain has been shortened by one methylene unit.

Experimental

In Figure 2 is outlined the synthetic sequence utilized in the synthesis of 24-nor-25-OH-D₃, 4.

Cholenic acid acetate, 5, was converted to its methyl ester, 6, in 94% yield [mp 154-56°; lit (7) 154-56°] using excess diazomethane generated by the action of base on bis-(N-methyl-N-nitroso)terephthalamide (8). Allylic bromination of 6 (1,3-dibromo-5,5-dimethylhydantoin in refluxing benzene/hexane, 1:1) followed by dehydrobromination (refluxing s-collidine, 30 min) (9) afforded after chromatography (10% AgNO₃-silica gel, petroleum ether-ether) a 46% yield of the 5,7-diene, 7 [mp 124-27°; lit (7) 125-27°; uv λ max 293 (ε6300), 282 (ε11,000), 271 (ε10,300) nm]. Alkylation of the latter (r.t., 24 hrs) in tetrahydrofuran with methyl lithium (1.8 M in ether) yielded after crystallization (methanol) the provitamin diene-diol, 8 (97%) [uv λ max 293 (ε5860), 282 (ε9700), 271 (ε9100); nmr τ 4.40 and 4.62 (H_{6,7}, ABq, J_{AB} ≈ 6Hz), 6.13-6.75 (H_{3α}, br m), 6.52 (C₂₅OH, s), 8.79 (C_{26,27}CH₃, s), 9.02 (C₂₁CH₃, d, J ≈ 6Hz), 9.04 (C₁₉CH₃, s), 9.35 (C₁₈CH₃, s); anal. calcd. for C₂₆H₄₂O₂·H₂O: C, 78.93; H, 11.21. Found: C, 78.55; H, 11.10], which was converted to the desired vitamin 4 by ultraviolet irradiation on a 0.5 mg/ml solution of the provitamin (EtOH) using a Hanovia 450 medium pressure mercury lamp (4 min at 0°). Following repeated chromatography over 10% AgNO₃ impregnated silica gel ('Baker-Analyzed', 60-200 mesh; 1 x 80 cm column), the vitamin (colorless, 31% yield) was found [uv EtOH λ max 264 nm, λ min 227; nmr (CDCl₃) τ 3.72 and 3.99 (H_{6,7}, ABq, J_{AB} ≈ 11 Hz), 4.96 and 5.20 (H_{19Z} and H_{19E}, m and d), 5.79-6.37 (H_{3α}, br m), 8.80 (C_{26,27} CH₃, s), 9.46 (C₁₈CH₃, s); ms, m/e 386 (M⁺)] to be homogeneous in several TLC systems. The overall yield of 24-nor-25-OH-D₃ was 13% from 5.




Figure 2. Pathway for the chemical synthesis of 24-nor-25-OH-D₃, 4 from cholenic acid acetate, 5.

The analog was assayed along with vitamin D₃ and 25-OH-D₃ according to the procedure of Hibberd and Norman (10) for their ability to stimulate intestinal calcium transport and bone calcium mobilization in vitamin D deficient (rachitic) chicks. White Leghorn cockerels were raised for three weeks on a standard rachitogenic, low calcium diet (11) without vitamin D supplement. Three days before assay the chicks were placed on a zero calcium diet. The vitamin D elicited responses were determined by published procedures (6) as follows: the duodenum of lightly ether anaesthetized chicks was surgically exposed and 5 μ Ci $^{45}\text{Ca}^{2+}$ + 4 mg nonradioactive $^{40}\text{Ca}^{2+}$ carrier was placed into the small intestine. Thirty minutes later the animal was sacrificed by decapitation and the blood collected and allowed to clot. Intestinal calcium absorption was assessed by determining the amount of radioactivity present in a 0.2 ml aliquot of serum. Bone calcium mobilization response was directly quantitated via atomic absorption spectrometry on appropriately diluted samples of the serum. The results were expressed as mg Ca^{2+} /100 ml serum.

Results and Discussion

The results of the bioassays are shown in Tables 1 and 2.

From the data expressed in Table 1 it is quite evident that in the chick there is neither an intestinal calcium absorption nor bone calcium mobilization response elicited by the new analog 24-nor-25-OH-D₃. However, a very interesting observation was made when birds were dosed with vitamin D after a predose with 24-nor-25-OH-D₃. As shown in Table 2, animals receiving a predose of the nor analog had a significantly lowered response to vitamin D₃. Both intestinal calcium transport and bone calcium mobilization were affected. It

Table 1

Intestinal Calcium Absorption and Bone Calcium Mobilization Activity
of 24-Nor-25-Hydroxyvitamin D₃

Compound	Dose ^a	<u>n</u>	Intestinal Ca ²⁺ Absorption Assay ^b	Bone Ca ²⁺ Mobilization Assay ^b
	(nmoles)		CPM ⁴⁵ Ca ²⁺ / 0.2 ml serum \pm SD	Serum Ca ²⁺ (mg/100 ml) \pm SD
None	--	(19)	330 \pm 130	5.4 \pm 0.7
24-nor-25-OH-D ₃	97.5	(9)	385 \pm 100	5.4 \pm 0.5
Vitamin D ₃	97.5	(9)	1680 \pm 360*	7.3 \pm 0.9*
25-OH-D ₃	97.5	(8)	1640 \pm 250*	7.8 \pm 1.0*

^aTwenty-four hours before assay, birds received a single intraperitoneal dose of the indicated compound in 0.2 ml 1,3-propanediol/EtOH (3:1). Control birds received only 0.2 ml of the vehicle. At the time of assay the birds were killed and bone calcium mobilization and intestinal calcium transport activities were determined as described in the Methods. Data are expressed as mean \pm SD.

^bValues indicated by a * are significantly different from the control (-D) at $p < 0.001$.

should also be noted that the onset of this "inhibitory" activity occurred when the analog was given as little as twelve hours before vitamin D and the duration of "inhibition" was for at least 36 hours. The fact that the analog did not impair the biological response of 25-OH-D₃ (Table 2, bottom line) but does block the response of vitamin D suggests that its site of action may be in the liver. Ongoing experiments will attempt to determine the reason for the observed decrease in vitamin D activity. Results from a preliminary experiment which employed radioactive vitamin D₃ indicate that in the presence of 24-nor-25-OH-D₃ the metabolism of vitamin D₃ to 25-OH-D₃ is greatly impaired.

The inhibitory effect of predosing with 24-nor-25-OH-D₃ on the biological response on the chick to vitamin D represents the first known instance of

Table 2
Inhibition of Vitamin D₃ Activity by Predosing
with 24-Nor-25-OH-D₃^a

Compound	Time of Predose before D ₃	n	Intestinal Ca ²⁺ Absorption Assay ^b	Bone Ca ²⁺ Mobilization Assay ^b
			CPM ⁴⁵ Ca ²⁺ / 0.2 ml serum \pm SD	Serum Ca ²⁺ (mg/100 ml) \pm SD
None	--	(12)	180 \pm 70*	5.8 \pm 0.4*
Vitamin D ₃	--	(18)	930 \pm 380	8.1 \pm 0.9
NOR ^c + D ₃	12	(9)	400 \pm 190*	6.4 \pm 0.5*
NOR + D ₃	36	(9)	470 \pm 115*	6.0 \pm 0.4*
25-OH-D ₃	--	(14)	1200 \pm 180	7.1 \pm 0.6
NOR + 25-OH-D ₃	24	(10)	1475 \pm 150	8.5 \pm 0.9

^aThis experiment was done exactly as for that shown in Table 1 except three groups received one intraperitoneal predose of 32.5 nmoles of 24-nor-25-OH-D₃ analog at the indicated time before a 6.5 nmole dose of vitamin D₃ or 25-OH-D₃. Control groups received only an IP dose of vehicle. Data are expressed as mean \pm standard deviation.

^bValues indicated by a * are significantly different from the vitamin D₃ treated group $p < 0.001$.

^cNOR = 24-nor-25-OH-D₃

"anti-vitamin" activity in the calciferol field. It has been known for many years that the chick has an unusually stringent requirement with regard to allowable side chain structures. The 8 carbon side chain of cholesterol (as in vitamin D₃) is 10X more active than the 9 carbon branched side chain of ergosterol (as in vitamin D₂) (10). Further the chick can discriminate between the two epimers, 24R,25-(OH)₂-D₃ and 24S,25-(OH)₂-D₃ (11). Thus before the concept of an "anti-vitamin" is firmly established for 24-nor-25-OH-D₃, it will be important to assess its inhibitory effects in other animal systems; e.g. it is known that vitamin D₂ and D₃ are equivalently active in the rat.

In this respect Holick *et al.* (13) have obtained some preliminary data suggesting that in the rat, 24-nor-25-OH-D₃ (at a dose level of 25 µg or 65 nmoles) is active in stimulating bone calcium mobilization and is not significantly active in mediating intestinal calcium absorption. There are several disorders of vitamin D in man, e.g. vitamin D intoxication, and sarcoidosis where the availability of an anti-vitamin D compound might be of clinical utility. However much further work is necessary to validate thoroughly the concept of "anti-vitamin" in relation to the steroid 24-nor-25-OH-D₃ and to evaluate its potential usefulness.

Acknowledgments

The dedicated assistance of Ms. P. Roberts is acknowledged. This work was supported in part by USPHS grants AM-16,595 and AM-09012. AWN is the recipient of a USPHS Career Research Development Award 1-KD-AM-13,654. We are grateful to Canada Packers, Ltd., Toronto for a generous gift of 3β-hydroxycholeonic acid.

References

1. Norman, A. W. and Henry, H. (1974) Recent Progr. Hormone Res. 30, 431-473.
2. Omdahl, J. L. and DeLuca, H. F. (1973) Physiol. Rev. 53, 327-347.
3. Ponchon, G., Kennan, A. L. and DeLuca, H. F. (1969) J. Clin. Invest. 48, 2032-2037.
4. Fraser, D. and Kodicek, E. (1970) Nature 228, 764-766.
5. Norman, A. W., Midgett, R. J., Myrtle, J. F. and Nowicki, H. G. (1971) Biochem. Biophys. Res. Commun. 42, 1082-1087.
6. Johnson, R. L. and Okamura, W. H. (1975) Fed. Proc. 34, 894.
7. Haslewood, G. A. D. (1935) J. Chem. Soc. 224-228.
8. Moore, J. A. and Reed, D. E. (1961) Org. Synth. 41, 16-17.
9. Okamura, W. H., Mitra, M. N., Procsal, D. A. and Norman, A. W. (1975) Biochem. Biophys. Res. Commun. 65, 24-30.
10. Hibberd, K. and Norman, A. W. (1969) Biochem. Pharmacol. 18, 2347-2355.
11. Norman, A. W. and Wong, R. G. (1972) J. Nutrition 102, 1709-1718.
12. Henry, H., Norman, A. W., Taylor, A. N., Hartenbower, D. L. and Coburn, J. W. (1975) J. Nutrition, submitted for publication.
13. Holick, M. F., Garabedian, M. and DeLuca, H. F. (1972) Biochem. 11, 2715-2719.